← Back to all trials
Completed
NCT07820111
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
Conditions: Obese Diabetics, Obese Non Diabetic
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE3
Enrollment: 159
Sponsor: Zagazig University
Location: Najran Health Cluster Najran Ksa
Summary
titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
Abstract :
Background: This study that highlights the different effects of most used three GLP-RA Dulaglutide, Semaglutide, Tirazepetide among diabetic and non -diabetic participant as the well-known fact that they don't have only weight recuing effect but also many different effects on metabolic process including insulin sensitivity, lipid profile and NASH.
Materials and Methods:
This is a randomized controlled study involving a total of 159 participants, divided into 75 non-diabetic and 84 diabetic obese individuals. Participants were assigned to three drug groups, each receiving a once-weekly dose of Dulaglutide, Semaglutide, or Tirzepatide for a period of 24 weeks. Each drug group consisted of 53 individuals, subdivided into 25 non-diabetic and 28 diabetic participants.
Measurements were taken at three time points: pretreatment, 3 months post-treatment, and 6 months post-treatment. Each participant underwent a complete physical exam, and data was collected on weight, BMI, age, and sex and Laboratory tests. , also repeated measurements were taken at 3 and 6 months post-treatment. on metabolic processes, weight reduction, and insulin sensitivity, particularly in diabetic individuals, as well as effects on lipid profiles and liver enzymes, weight reduction, BMI, HbA1c, TYG-index, triglycerides, and HDL-C levels. total cholesterol (Tc) and liver enzymes.
Data were collected, and statistical analyses were conducted afterward.
Eligibility Criteria
Inclusion Criteria:
* overweight or obese, diabetic, or non-diabetic
Exclusion Criteria:
* Patients who will refuse to be enrolled in the study or refuse to sign the consent
Source: ClinicalTrials.gov (NCT07820111). StuddyBuddy aggregates publicly available trial information.